Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18994018 | 1.00 | CHRM2 (0.33) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL20833341 | 0.96 | CYP2D6 (0.30) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL18967185 | 0.86 | MEN1 (0.32) | — | |
| SCHEMBL2741653 | 0.83 | MAPK1 (0.30) | CHRM2CHRM4CHRM1CHRM3MAPK1 | |
| SCHEMBL24754299 | 0.79 | — | — | |
| SCHEMBL29308169 | 0.79 | — | — | |
| SCHEMBL16253702 | 0.79 | — | — | |
| SCHEMBL15395994 | 0.79 | — | — | |
| SCHEMBL25908860 | 0.79 | MAPT (0.32) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL20923608 | 0.79 | CYP2D6 (0.36) | CHRM2CHRM4CHRM1CHRM3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017098328-A2 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHAMACEUTICALS, INC. (BB) | 2017-06-15 | — | — | WO | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-8921514-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | CHRM2 4875/4885CHRM4 4780/4885CHRM1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.